DUBLIN, Ireland - New York Stock Exchange-listed IQVIA, a global provider of information, innovative technology solutions and contract research services in the pharmaceuticals sector, on Friday announced it was creating a hundred new jobs in Dublin, Ireland.
The new roles at IQVIA's Dublin East Point Campus will consist of highly skilled, full-time jobs in the areas of Clinical Project Management, Data Management, Drug Safety and Biostatistics. In particular, IQVIA says it is recruiting Pharmacovigilance specialists, across a variety of safety services spanning both clinical trials and medicines safety. There will also be a number of positions made available for life science graduates.
The company said Friday recruitment is underway and IQVIA expects the roles to be filled in the first half of this year.
In Ireland since 1990, IQVIA (formerly IMS Health and Quintiles) has been a clinical research pioneer for the pharmaceutical industry.
The additional roles, the company says, will increase IQVIA's capability to serve its customer base across Europe and globally. In addition to supporting its global operations, IQVIA's activities in Ireland include: tracking the pharmaceutical market, conducting market research, providing consulting services across the healthcare spectrum, and offering contract resources to support healthcare companies commercialise their innovative medicines.
"Ireland is a strategically important location for IQVIA, and today's announcement represents a significant step in increasing our capability to serve our pharma customers across Europe and the world. Ireland has a rich base of life sciences talent, is a great place to do business and we look forward to continuing to grow our business here," Martin Giblin, SVP, Global Head, Centralized Monitoring Services, Country Head IQVIA Ireland said Friday.
Irish Minister for Finance, Public Expenditure and Reform, Paschal Donohoe, said "Ireland's pharma industry continues to grow and today's announcement by IQVIA is another exciting development. Ireland's ability to retain companies such as IQVIA is a testament to our attractive business environment, robust regulatory framework, and skilled labour force. We are delighted to see an industry leader that supports the pharma and life science sector continuing its expansion, which will enable IQVIA to serve more customers with their innovative technology around the world."
Tommy Fanning, Head of Biopharmaceuticals, IDA Ireland, said: "We are delighted with today's announcement as it is a vote of confidence in Ireland and adds significantly to the expert cluster in biopharma and clinical research. IQVIA's decision to build on its existing strong presence provides high quality challenging jobs which fit well with the future of the life sciences sector in Ireland."
Pictured: Tommy Fanning, IDA Ireland (left) , Minister for Finance Paschal Donohoe (centre) and Martin Giblin, MD IQVIA Ireland (right).